Clinical Chemistry Test Guide

ALT Blood Test

Understanding Alanine Aminotransferase from liver-cell injury and blood sample collection to analyser measurement, Biomedical Scientist review and clinical decision-making.

Quick Facts

Alanine Aminotransferase (ALT) is a Clinical Chemistry enzyme test used mainly to support assessment of hepatocellular injury. It is interpreted with the patient’s clinical history, medication history, sample quality, local reference interval and wider liver-test pattern.

BiomarkerAlanine Aminotransferase
Also known asALT / ALAT / formerly SGPT
Main tissue associationLiver hepatocytes
DepartmentClinical Chemistry
SampleSerum or validated plasma
MethodIFCC-type enzymatic method
MeasurementNADH decrease at 340 nm
Report unitsU/L, laboratory dependent
Educational scope: this guide explains laboratory medicine principles. It does not replace local laboratory SOPs, manufacturer instructions, clinical guidelines or medical advice.

Clinical Significance

ALT is an intracellular aminotransferase enzyme. In routine clinical practice it is requested as part of a liver profile or wider biochemical screen to help identify, monitor or investigate patterns of liver-cell injury. ALT activity in blood usually remains low when hepatocyte membranes are intact. When hepatocytes are injured, enzyme leakage into the circulation can increase measured ALT activity.

ALT is often described as more liver-associated than AST, although it is not completely liver-specific. Small amounts are found in other tissues, and clinical interpretation must take account of symptoms, medication, alcohol intake, metabolic risk factors, viral hepatitis risk, muscle injury, pregnancy context and other biochemical results.

Common clinical usesAssessing hepatocellular injury

ALT contributes to recognising hepatocellular patterns, especially when compared with AST, ALP, GGT and bilirubin.

MonitoringDisease and treatment trends

Serial ALT results may support monitoring of chronic liver disease, medication effects, metabolic-associated steatotic liver disease and recovery after acute injury.

Key interpretation principle: ALT is a marker, not a diagnosis. The same ALT result may mean different things in different patients.

What is ALT?

ALT participates in amino acid metabolism by catalysing transfer of an amino group between alanine and 2-oxoglutarate. In liver-cell injury, intracellular ALT can leak into the blood and become measurable in serum or plasma.

ALT in context

ALT is clinically useful because it links biochemistry, hepatocyte integrity and laboratory measurement.

1Healthy hepatocytesALT is retained inside liver cells.
2Cell injuryMembrane integrity is disrupted.
3ALT leaks outEnzyme enters the bloodstream.
4Blood sampleALT activity is present in serum/plasma.
5Laboratory testThe analyser calculates enzyme activity.

Learning point

ALT is interpreted with the full liver-test pattern and local clinical pathway.

Principle of the Assay

Many modern Clinical Chemistry ALT methods use an IFCC-type enzymatic approach. ALT catalyses a transamination reaction, and a coupled LDH reaction allows the analyser to monitor NADH oxidation by measuring the decrease in absorbance at 340 nm.

L-Alaninesubstrate
2-Oxoglutarateco-substrate
ALTenzyme activity
Pyruvatereaction product
LDH
LDHcoupled enzyme
L-Lactatereaction product
NADHNAD+
NADH oxidationNADH to NAD+
ALT Activitycalculated rate
Enzymatic reaction

ALT transfers an amino group from alanine to 2-oxoglutarate, forming pyruvate and glutamate under assay conditions.

Why absorbance decreases

Pyruvate is converted to lactate by LDH while NADH is oxidised to NAD+. NADH absorbs at 340 nm, so absorbance falls as the reaction proceeds.

Activity calculation

The analyser measures the rate of absorbance decrease and converts this rate into ALT activity, typically reported in U/L.

Method-specific details: reagent composition, sample types, measuring interval, linearity and interference limits must match the current Abbott Alinity A-ALT method sheet before final release.

Laboratory Workflow

An ALT result is not just a number. It travels through pre-analytical, analytical and post-analytical stages before it reaches a clinical decision.

1
Patient

Patient attends GP, clinic, ward or emergency setting.

2
Collection

Blood collected into a locally validated tube.

3
Transport

Specimen transported according to local policy.

4
Reception

Request, identity and sample suitability checked.

5
Centrifugation

Serum or plasma separated for analysis.

6
Analysis

ALT measured on validated chemistry analyser.

7
Internal QC

QC reviewed before patient results are released.

8
BMS Review

Flags, indices, trends and plausibility reviewed.

9
Authorisation

Result released according to governance rules.

10
Decision

Clinician interprets result with patient context.

Specimen Requirements

ALT is commonly measured in serum or plasma on automated Clinical Chemistry analysers. Accepted tube types and stability must follow the current method sheet and local laboratory SOP.

SerumCommon specimen type for routine Clinical Chemistry. Allow clotting and centrifuge according to local procedure.
Lithium heparin plasmaOften used for chemistry profiles where locally validated.
Other validated plasmaUse only if accepted by the current method and local SOP.
Unsuitable specimensIncorrect tube, inadequate labelling, severe sample quality issues or compromised transport may require rejection.
Storage and stability: do not generalise from memory. Insert the laboratory-approved room temperature, refrigerated and frozen stability after checking the active Abbott insert and local SOP.

Pre-analytical and Analytical Limitations

Limitations occur before, during and after analysis. A robust ALT guide must explain these clearly because many “abnormal results” first require assessment of specimen integrity and analytical validity.

Green

  • Correct patient and sample identification
  • Validated tube type
  • Appropriate separation and transport
  • QC acceptable before reporting

Amber

  • Minor delay or borderline sample quality
  • Unexpected result requiring trend review
  • Need to compare with other liver tests
  • Possible medication or exercise contribution

Red

  • Severe haemolysis or analyser interference flag
  • Incorrect tube or unlabelled sample
  • QC failure or calibration concern
  • Result unsafe to release without review
Why haemolysis matters: haemolysis may affect several chemistry assays and may indicate poor sample integrity. The decision to report, reject or comment must follow analyser indices and local policy.

Quality Assurance

Quality assurance protects patients by ensuring that the ALT result is analytically valid before it is used clinically.

CalibrationLinks instrument response to the validated analytical system and method requirements.
Internal Quality ControlMonitors routine performance and detects shifts or imprecision before patient result release.
Westgard-style reviewStructured QC rules support consistent action when control results are outside expectation.
EQA / proficiency testingExternal comparison supports confidence in performance against peer laboratories.
Method verificationPrecision, bias, reportable range and interference claims should be verified before method use.
BMS authorisationBiomedical Scientists review flags, QC, trends, sample quality and local escalation rules.

Result Interpretation

ALT interpretation depends on the local reference interval and clinical context. A result should be viewed alongside AST, ALP, GGT, bilirubin, albumin, total protein, coagulation where appropriate and the patient’s history.

Within intervalMildly raisedModerately raisedMarkedly raised
Within local reference interval

A result within the laboratory interval may be reassuring, but it does not exclude all liver disease. Clinical context remains important.

Mild ALT elevation

Mild elevation may be seen with metabolic-associated steatotic liver disease, medication effects, alcohol-related disease, viral hepatitis, recent strenuous exercise or other clinical contexts. Repeating the test or adding further investigations depends on local pathways.

Marked ALT elevation

Marked elevation may suggest significant hepatocellular injury and requires clinical correlation. Urgency depends on symptoms, bilirubin, coagulation, renal function, medication/toxin history and local escalation criteria.

ALT compared with AST

ALT and AST patterns can support interpretation, but ratios are not diagnostic in isolation. Muscle injury, alcohol-related disease, advanced liver disease and acute hepatocellular injury can alter the pattern.

Biomedical Scientist Insight

Why the analyser result is reviewed

The analyser can generate flags, indices and reaction data. Biomedical Scientists review these alongside QC and local rules to decide whether the result is technically valid.

Why samples may be rejected

Incorrect patient details, wrong tube, insufficient sample, severe haemolysis, leakage or compromised transport can make a result unsafe to report.

Why QC matters

ALT results influence clinical decisions. QC failure may indicate analytical drift or imprecision, so patient results should not be released until the issue is resolved.

Why abnormal results need context

A high ALT may be clinically expected, new, worsening, urgent or inconsistent with the wider picture. Interpretation depends on trends and the full biochemical pattern.

Clinical Case

Patient scenarioRaised ALT in primary care

An adult patient has fatigue and non-specific abdominal discomfort. ALT is raised with mild GGT elevation. Bilirubin and albumin are within the local reference interval.

Laboratory questionWhat should be reviewed before release?

Sample quality, haemolysis/icterus/lipaemia indices, analyser flags, QC status, previous results and the wider liver-test pattern.

Reveal learning points

ALT elevation should be interpreted with history and other results. The Biomedical Scientist’s role is to ensure the analytical result is valid and appropriately authorised; the clinician decides the diagnostic and management pathway.

Frequently Asked Questions

What does ALT measure?

ALT testing measures enzyme activity in serum or plasma. Increased activity can occur when hepatocytes release intracellular enzyme into the blood.

Does high ALT always mean liver disease?

No. ALT is associated with hepatocellular injury, but it is not a diagnosis by itself. Medication, alcohol, metabolic risk factors, viral hepatitis, muscle injury and other clinical contexts may need consideration.

Can exercise affect ALT?

Strenuous exercise may affect some liver and muscle-related enzymes. Interpretation should include history and other test results, especially AST and creatine kinase if muscle injury is suspected.

How is ALT measured in the laboratory?

Many methods use an enzymatic reaction coupled to NADH oxidation. The analyser monitors a decrease in absorbance at 340 nm and calculates ALT activity from the reaction rate.

Why do reference intervals differ between laboratories?

Reference intervals depend on method, analyser, population, verification process and local governance. Always use the interval supplied with the patient result.

Revision Notes

ALT one-page summary

PDF revision sheet to be generated from this master guide after scientific review.

Download PDF

Interactive Quiz

Use these questions to check understanding. Future versions can support scoring and certificate generation.

Q1. What is the main clinical use of ALT?
Assessment of hepatocellular injury patternDiagnosis of anaemiaMeasurement of renal filtrationCoagulation screening
Reveal feedback

Correct answer: assessment of hepatocellular injury pattern. ALT is interpreted with other liver tests and clinical context.

Q2. Why does absorbance fall in the ALT assay?
NADH is oxidised to NAD+Albumin is precipitatedHaemoglobin is measured directlyBilirubin is converted to biliverdin
Reveal feedback

Correct answer: NADH is oxidised to NAD+. NADH absorbs at 340 nm, so its consumption causes absorbance to decrease.

Q3. What should happen before reporting patient ALT results?
QC and analyser flags should be acceptableReference intervals should be ignoredThe result should diagnose the patient aloneThe sample type no longer matters
Reveal feedback

Correct answer: QC and analyser flags should be acceptable. Analytical quality is essential before result release.

Q4. Which result pattern needs clinical context?
All ALT patternsOnly very high ALTOnly normal ALTOnly ALT below the interval
Reveal feedback

Correct answer: all ALT patterns. Even a normal ALT may need context if symptoms or risk factors are present.

Q5. Who authorises or technically validates results according to local laboratory rules?
Biomedical Scientist / authorised laboratory staffThe patientThe courierThe website
Reveal feedback

Correct answer: Biomedical Scientists or authorised laboratory staff review results according to local governance.

References and Source Framework

This guide is written as original educational content using a source hierarchy: current manufacturer method sheet, local laboratory information, core textbooks, IFCC/CLSI/ISO principles and professional guidance.

Abbott Diagnostics. Alinity c Alanine Aminotransferase A-ALT package insert / method documentation. Current user-supplied version to be checked for exact specimen types, limitations, interference claims, measuring range and stability before final local publication.
Burtis, C.A., Bruns, D.E. and Tietz contributors. Tietz Fundamentals / Textbook of Clinical Chemistry and Molecular Diagnostics. Used for clinical chemistry principles, enzyme methodology and interpretation framework.
McPherson, R.A. and Pincus, M.R. Henry’s Clinical Diagnosis and Management by Laboratory Methods. Used for clinical laboratory interpretation framework.
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Enzyme standardisation and laboratory medicine education resources.
Clinical and Laboratory Standards Institute (CLSI). Method verification, quality systems and clinical laboratory standards framework.
University Hospitals Birmingham Pathology. Public pathology information and laboratory governance context, including ISO 15189 accreditation information and test database signposting.
NICE, NHS, IBMS and RCPath guidance to be added where a specific clinical pathway, professional standard or patient-facing recommendation is cited.